NBIX vs. PODD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NBIX and PODD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | NBIX | PODD |
|---|---|---|
| Company Name | Neurocrine Biosciences, Inc. | Insulet Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 13.21 billion USD | 23.44 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | May 23, 1996 | May 15, 2007 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of NBIX and PODD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NBIX | PODD |
|---|---|---|
| 5-Day Price Return | 1.46% | 5.45% |
| 13-Week Price Return | 8.48% | 2.20% |
| 26-Week Price Return | 14.00% | 18.03% |
| 52-Week Price Return | -10.13% | 69.97% |
| Month-to-Date Return | 3.90% | 15.46% |
| Year-to-Date Return | -2.40% | 27.55% |
| 10-Day Avg. Volume | 0.84M | 0.81M |
| 3-Month Avg. Volume | 1.17M | 0.77M |
| 3-Month Volatility | 23.38% | 28.51% |
| Beta | 0.21 | 1.42 |
Profitability
Return on Equity (TTM)
NBIX
13.22%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, NBIX’s Return on Equity of 13.22% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
PODD
18.43%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
PODD’s Return on Equity of 18.43% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
NBIX
13.88%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
NBIX’s Net Profit Margin of 13.88% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
PODD
10.01%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
PODD’s Net Profit Margin of 10.01% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
NBIX
19.72%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
NBIX’s Operating Profit Margin of 19.72% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
PODD
12.01%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
PODD’s Operating Profit Margin of 12.01% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NBIX | PODD |
|---|---|---|
| Return on Equity (TTM) | 13.22% | 18.43% |
| Return on Assets (TTM) | 9.39% | 7.21% |
| Net Profit Margin (TTM) | 13.88% | 10.01% |
| Operating Profit Margin (TTM) | 19.72% | 12.01% |
| Gross Profit Margin (TTM) | 98.49% | 70.74% |
Financial Strength
Current Ratio (MRQ)
NBIX
3.20
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
NBIX’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
PODD
2.26
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
PODD’s Current Ratio of 2.26 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
NBIX
0.00
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
NBIX’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
PODD
0.96
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
PODD’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.96. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
NBIX
6.75
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
NBIX’s Interest Coverage Ratio of 6.75 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
PODD
33.28
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
PODD’s Interest Coverage Ratio of 33.28 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | NBIX | PODD |
|---|---|---|
| Current Ratio (MRQ) | 3.20 | 2.26 |
| Quick Ratio (MRQ) | 3.10 | 1.55 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.96 |
| Interest Coverage Ratio (TTM) | 6.75 | 33.28 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
PODD
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
PODD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
NBIX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
PODD
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
PODD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | NBIX | PODD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
NBIX
37.70
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
NBIX’s P/E Ratio of 37.70 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
PODD
98.83
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
At 98.83, PODD’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Equipment & Supplies industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
NBIX
5.23
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
NBIX’s P/S Ratio of 5.23 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
PODD
9.89
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
With a P/S Ratio of 9.89, PODD trades at a valuation that eclipses even the highest in the Health Care Equipment & Supplies industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
NBIX
4.62
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
NBIX’s P/B Ratio of 4.62 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
PODD
15.11
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
At 15.11, PODD’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | NBIX | PODD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 37.70 | 98.83 |
| Price-to-Sales Ratio (TTM) | 5.23 | 9.89 |
| Price-to-Book Ratio (MRQ) | 4.62 | 15.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 24.84 | 61.02 |